Arlak Biotech Profile
Key Indicators
- Authorised Capital ₹ 0.30 M
as on 22-10-2024
- Paid Up Capital ₹ 0.30 M
as on 22-10-2024
- Company Age 17 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 3.00 Cr
as on 22-10-2024
- Revenue -22.65%
(FY 2023)
- Profit -13.34%
(FY 2023)
- Ebitda 6.84%
(FY 2023)
- Net Worth 13.74%
(FY 2023)
- Total Assets 8.45%
(FY 2023)
About Arlak Biotech
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.30 M and a paid-up capital of Rs 0.30 M.
The company currently has active open charges totaling ₹3.00 Cr.
Umesh Kalra, Dhiraj Kalra, and Jyoti serve as directors at the Company.
- CIN/LLPIN
U24232PB2007PTC031093
- Company No.
031093
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
27 Apr 2007
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Patiala, Punjab, India
- Telephone
- Email Address
- Website
- Social Media
- Apps
What products or services does Arlak Biotech Private Limited offer?
Arlak Biotech Private Limited offers a wide range of products and services, including Nutraceuticals & Dietary Supplements, Nutritional Supplements, Common Disease Medicines, Antihistamines, Anti Infective Drugs & Medicines, Antibacterial Drugs, Antibiotic Tablets, Capsule & Syrup, Digestive System Drugs & Medicines, Antacid Drugs, Dietary Supplements.
Who are the key members and board of directors at Arlak Biotech?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Umesh Kalra  | Director | 27-Apr-2007 | Current |
| Dhiraj Kalra | Director | 27-Apr-2007 | Current |
| Jyoti | Director | 27-Apr-2007 | Current |
Financial Performance of Arlak Biotech.
Arlak Biotech Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 22.65% decrease. The company also saw a substantial fall in profitability, with a 13.34% decrease in profit. The company's net worth Soared by an impressive increase of 13.74%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Arlak Biotech?
In 2023, Arlak Biotech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 22 Dec 2015 | ₹3.00 Cr | Open |
How Many Employees Work at Arlak Biotech?
Arlak Biotech has a workforce of 2 employees as of Oct 22, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Arlak Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Arlak Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
